Rein Therapeutics Debt-to-Equity Ratio Growth & History (RNTX)

Rein Therapeutics's debt-to-equity ratio was 0.00 for fiscal 2024.

View full Rein Therapeutics company overview

Rein Therapeutics annual debt-to-equity ratio history

Rein Therapeutics annual debt-to-equity ratio

Fiscal yearPeriod endedDebt-to-equity ratioChangeGrowth
20242024-12-310.00−0.00
20232023-12-310.00−0.00−81.05%
20222022-12-310.00−0.00−30.15%
20212021-12-310.00
20192019-12-310.310.04+13.81%
20182018-12-310.28

Rein Therapeutics debt-to-equity ratio trends

Over the last five fiscal years, Rein Therapeutics's debt-to-equity ratio decreased from 0.31 to 0.00, a change of −0.31. The latest reported quarter, Q1 2026, shows 0.42.

About the metric

What the debt-to-equity ratio means

The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.

Calculation and source

How debt-to-equity is calculated

TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Rein Therapeutics source filings ↗

Community posts

It’s quiet here.

No posts about RNTX yet. Start the conversation.

Write the first post